No correlative trends were observed between clinical response and immunohistochemistry expression scores of LAG-3, PD-1, or MHC class II, likely due to the small number of patients, low objective response rates, multiple tumor types, and different dose levels tested. The gene discussed is LAG3; the disease is neoplasm.